Coagulation and anticoagulation in idiopathic pulmonary fibrosis

European Respiratory Review

Volumn 24, Issue 137, 2015, Pages 392-399

  Crooks, Michael G ^a   Hart, Simon P ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8C; CREATININE; D DIMER; DABIGATRAN; FIBRIN; FIBRINOGEN; HOMOCYSTEINE; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; PREDNISOLONE; RIVAROXABAN; THROMBIN INHIBITOR; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; TRANSFORMING GROWTH FACTOR BETA; WARFARIN;

ACUTE KIDNEY FAILURE; ANTICOAGULANT THERAPY; ATRIAL FIBRILLATION; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CREATININE BLOOD LEVEL; FIBRINOLYSIS; FIBROSING ALVEOLITIS; HEMATURIA; HUMAN; HYPERCOAGULABILITY; INCIDENCE; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY HEMORRHAGE; LUNG FIBROSIS; LUNG HEMORRHAGE; MONOTHERAPY; MORTALITY; NONHUMAN; POPULATION RESEARCH; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; THROMBOCYTE ACTIVATION; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VENOUS THROMBOEMBOLISM; ANIMAL; BLOOD; BLOOD CLOTTING; DISEASE COURSE; DISEASE MODEL; DRUG EFFECTS; IDIOPATHIC PULMONARY FIBROSIS; LUNG ALVEOLUS; METABOLISM; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ANIMALS; ANTICOAGULANTS; BLOOD COAGULATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; PULMONARY ALVEOLI; RISK ASSESSMENT; RISK FACTORS; THROMBOSIS; TREATMENT OUTCOME;

EID: 84940647099     PISSN: 09059180     EISSN: 16000617     Source Type: Journal    
DOI: 10.1183/16000617.00008414     Document Type: Review

References (52)

1. Cottin V. Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey. Eur Respir Rev 2014; 23: 225-230.
2. Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med 2008; 178: 1257-1261.
3. Sode BF, Dahl M, Nielsen SF, et al. Venous thromboembolism and risk of idiopathic interstitial pneumonia: a nationwide study. Am J Respir Crit Care Med 2010; 181: 1085-1092.
4. Sprunger DB, Olson AL, Huie TJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J 2012; 39: 125-132.
5. Fujii M, Hayakawa H, Urano T, et al. Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis. Thromb Res 2000; 99: 111-117.
6. Kotani I, Sato A, Hayakawa H, et al. Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis. Thromb Res 1995; 77: 493-504.
7. Navaratnam V, Fogarty AW, McKeever T, et al. Presence of a prothrombotic state in people with idiopathic pulmonary fibrosis: a population-based case-control study. Thorax 2014; 69: 207-215.
8. Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest 2005; 128: 1475-1482.
9. Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 186: 88-95.
10. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999; 78: 285-291.
11. Chambers RC. Role of coagulation cascade proteases in lung repair and fibrosis. Eur Respir J 2003; 22: Suppl. 44, 33s-35s.
12. Wygrecka M, Markart P, Ruppert C, et al. Cellular origin of pro-coagulant and (anti)-fibrinolytic factors in bleomycin-injured lungs. Eur Respir J 2007; 29: 1105-1114.
13. Chapman HA, Allen CL, Stone OL. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis 1986; 133: 437-443.
14. Wygrecka M, Kwapiszewska G, Jablonska E, et al. Role of protease-activated receptor-2 in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011; 183: 1703-1714.
15. Eitzman DT, McCoy RD, Zheng X, et al. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene. J Clin Invest 1996; 97: 232-237.
16. Bertozzi P, Astedt B, Zenzius L, et al. Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome. N Engl J Med 1990; 322: 890-897.
17. Senoo T, Hattori N, Tanimoto T, et al. Suppression of plasminogen activator inhibitor-1 by RNA interference attenuates pulmonary fibrosis. Thorax 2010; 65: 334-340.
18. Idell S, Koenig KB, Fair DS, et al. Serial abnormalities of fibrin turnover in evolving adult respiratory distress syndrome. Am J Physiol 1991; 261: L240-L248.
19. Bozza FA, Shah AM, Weyrich AS, et al. Amicus or adversary: platelets in lung biology, acute injury, and inflammation. Am J Respir Cell Mol Biol 2009; 40: 123-134.
20. Zucker-Franklin D, Philipp CS. Platelet production in the pulmonary capillary bed: new ultrastructural evidence for an old concept. Am J Pathol 2000; 157: 69-74.
21. Tabuchi A, Kuebler WM. Endothelium-platelet interactions in inflammatory lung disease. Vascul Pharmacol 2008; 49: 141-150.
22. Maclay JD, McAllister DA, Johnston S, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011; 66: 769-774.
23. Kaplan DR, Chao FC, Stiles CD, et al. Platelet alpha granules contain a growth factor for fibroblasts. Blood 1979; 53: 1043-1052.
24. Fava RA, Casey TT, Wilcox J, et al. Synthesis of transforming growth factor-β1 by megakaryocytes and its localization to megakaryocyte and platelet alpha-granules. Blood 1990; 76: 1946-1955.
25. Antoniades HN, Bravo MA, Avila RE, et al. Platelet-derived growth factor in idiopathic pulmonary fibrosis. J Clin Invest 1990; 86: 1055-1064.
26. Sime PJ, Xing Z, Graham FL, et al. Adenovector-mediated gene transfer of active transforming growth factor-β1 induces prolonged severe fibrosis in rat lung. J Clin Invest 1997; 100: 768-776.
27. Cao B, Guo Z, Zhu Y, et al. The potential role of PDGF, IGF-1, TGF-β expression in idiopathic pulmonary fibrosis. Chin Med J (Engl) 2000; 113: 776-782.
28. Piguet PF, Vesin C. Pulmonary platelet trapping induced by bleomycin: correlation with fibrosis and involvement of the β2 integrins. Int J Exp Pathol 1994; 75: 321-328.
29. Fahim A, Crooks MG, Morice AH, et al. Increased platelet binding to circulating monocytes in idiopathic pulmonary fibrosis. Lung 2014; 192: 277-284.
30. Tomashefski JF Jr, Davies P, Boggis C, et al. The pulmonary vascular lesions of the adult respiratory distress syndrome. Am J Pathol 1983; 112: 112-126.
31. Bargagli E, Madioni C, Bianchi N, et al. Serum analysis of coagulation factors in IPF and NSIP. Inflammation 2014; 37: 10-16.
32. Greaves M, Pickering C, Knight G, et al. Changes in the factor VIII complex in diabetic ketoacidosis: evidence of endothelial cell damage? Diabetologia 1987; 30: 160-165.
33. Carvalho AC, Bellman SM, Saullo VJ, et al. Altered factor VIII in acute respiratory failure. N Engl J Med 1982; 307: 1113-1119.
34. Grant K, Rodvien R, Mielke CH Jr. Altered factor VIII complexes in patients with acute respiratory insufficiency. Thromb Haemost 1978; 40: 326-334.
35. Kamphuisen PW, Eikenboom JC, Bertina RM. Elevated factor VIII levels and the risk of thrombosis. Arterioscler Thromb Vasc Biol 2001; 21: 731-738.
36. Kolb M, Collard HR. Staging of idiopathic pulmonary fibrosis: past, present and future. Eur Respir Rev 2014; 23: 220-224.
37. Maher TM. Disease stratification in idiopathic pulmonary fibrosis: the dawn of a new era? Eur Respir J 2014; 43: 1233-1236.
38. Ryerson CJ, Corte TJ, Collard HR, et al. A global registry for idiopathic pulmonary fibrosis: the time is now. Eur Respir J 2014; 44: 273-276.
39. Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate. Kidney Int 2011; 80: 181-189.
40. Brodsky SV, Satoskar A, Chen J, et al. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases. Am J Kidney Dis 2009; 54: 1121-1126.
41. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172.
42. Bendstrup E, Hillberg O. Is warfarin the right anticoagulant in idiopathic pulmonary fibrosis? Am J Respir Crit Care Med 2012; 186: 693.
43. Bogatkevich GS, Tourkina E, Silver RM, et al. Thrombin differentiates normal lung fibroblasts to a myofibroblast phenotype via the proteolytically activated receptor-1 and a protein kinase C-dependent pathway. J Biol Chem 2001; 276: 45184-45192.
44. Bogatkevich GS, Ludwicka-Bradley A, Silver RM. Dabigatran, a direct thrombin inhibitor, demonstrates antifibrotic effects on lung fibroblasts. Arthritis Rheum 2009; 60: 3455-3464.
45. Howell DC, Goldsack NR, Marshall RP, et al. Direct thrombin inhibition reduces lung collagen, accumulation, and connective tissue growth factor mRNA levels in bleomycin-induced pulmonary fibrosis. Am J Pathol 2001; 594: 1383-1395.
46. Bogatkevich GS, Ludwicka-Bradley A, Nietert PJ, et al. Antiinflammatory and antifibrotic effects of the oral direct thrombin inhibitor dabigatran etexilate in a murine model of interstitial lung disease. Arthritis Rheum 2011; 63: 1416-1425.
47. Jalota A, Scarabelli TM, Saravolatz L, et al. Novel anticoagulants for stroke prevention in patients with atrial fibrillation. Cardiovasc Drugs Ther 2014; 28: 247-262.
48. Prins MH, Lensing AW, Bauersachs R, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21.
49. Agnelli G, Buller HR, Cohen A, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808.
50. Scotton CJ, Krupiczojc MA, Königshoff M, et al. Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury. J Clin Invest 2009; 119: 2550-2563.
51. Blanc-Brude OP, Chambers RC, Leoni P, et al. Factor Xa is a fibroblast mitogen via binding to effector-cell protease receptor-1 and autocrine release of PDGF. Am J Physiol Cell Physiol 2001; 281: C681-C689.
52. Blanc-Brude OP, Archer F, Leoni P, et al. Factor Xa stimulates fibroblast procollagen production, proliferation, and calcium signaling via PAR1 activation. Exp Cell Res 2005; 304: 16-27.